How do buyers, sellers and investors in life sciences safeguard regulatory compliance during M&A and post-merger integration?
We support buyers, sellers and investors in the life sciences sector through regulatory due diligence, QMS integration and post-merger compliance, from assessing the target to transferring marketing authorizations and certificates to the new owner. The real hurdle is rarely the purchase agreement; it is the sequence after closing. Anyone who fails to set up authorization transfer, QMS integration and authority communication in parallel and early on risks a phase without valid responsibilities, during which products are left regulatorily unsupervised.
- Pharma
- Biotech
- MedTech
- IVD
Overview
What compliance risks arise in life sciences M&A?
Support for buyers, sellers and investors across the entire M&A process · GMP, ISO 13485:2016, EUDAMED transfer
Last updated: 2026-06-13
Mergers and acquisitions in life sciences rarely fail on price; they fail on regulatory liabilities that do not become fully visible during due diligence and that determine the integration effort after closing. Four levers decide how the process unfolds:
- Regulatory gaps at the target go undetected: open authority communication, pending inspection findings, CAPA backlogs or incomplete authorization dossiers are not recognized as liabilities in the data room and hit the buyer after closing.
- QMS integration is underestimated: two systems operated under ISO 13485:2016 or EU GMP collide in their processes, document control and responsibilities. Without a gap analysis, it remains unclear which system takes the lead.
- Marketing authorizations, certificates and licenses must be transferred to the new owner: in the EU via variation procedures with the competent authorities, for medical devices via the notified body and EUDAMED under EU 2017/745 or EU 2017/746 respectively, and in the US via ownership transfer with the FDA.
- Differing quality and compliance cultures delay integration: divergent policies, training levels and escalation paths create friction that cannot be resolved through org charts, only through active alignment.
Services
How we support you
Regulatory due diligence
Assessment of the target for regulatory risks: authorization status, QMS maturity, open authority communication, CAPA backlog, ongoing inspection findings and product recalls. The result is a structured red-flag report as a basis for the investment decision.
QMS gap analysis & integration strategy
Comparison of both companies' QMS for compatibility and standards compliance under ISO 13485:2016 or ISO 9001:2015 as well as EU GMP. The result is a QMS integration strategy with milestones, responsibilities and a leading target system.
Post-merger compliance management
Support for the regulatory integration: authorization transfers via the competent authorities, notified body communication and EUDAMED updates under EU 2017/745 and EU 2017/746. The result is a change control plan for all regulatorily relevant changes in the integration process.
Learn more →Cultural integration & quality culture
Support for quality culture integration: alignment of quality policies, training programs and escalation paths across both organizations. The result is a documented integration plan for the quality culture, with identified friction points and countermeasures.
Carve-out & seller support
Preparation of the sell side: organizing the regulatory data room, resolving open findings and structuring the transferable authorizations and certificates. The result is a robustly documented regulatory status that surfaces red flags before the process begins.
How we work together
What it comes down to
In life sciences transactions, the risk lies not in the contract but in the sequence after closing. Regulatory due diligence first reveals which authorizations, certificates and open CAPA cases are actually transferable and which are tied to the maturity of the technical documentation or the approval of the notified body. Only then can the QMS integration be planned: deciding which of the two systems operated under ISO 13485:2016 or EU GMP takes the lead governs every further step of document control. Anyone who leaves this question open and continues both systems in parallel creates conflicting processes that surface as a nonconformity in the next surveillance audit.
The critical bottleneck is the authorization transfer. Variation procedures in the EU, ownership transfer with the FDA and the EUDAMED update under EU 2017/745 and EU 2017/746 have lead times that must not begin only after closing. If they are set up in parallel with the operational integration, regulatory responsibility for every product stays clearly assigned throughout. If they are deferred, a phase arises in which a product is formally supervised by neither the seller nor the buyer. It is precisely this gap that surfaces in the next inspection under EudraLex Volume 4 or 21 CFR Part 211.
Our approach
Our approach
Step
Result
Regulatory due diligence
Red-flag report with assessed regulatory risks, CAPA backlog, open findings and authorizations subject to transfer, serving as a decision basis.
QMS gap analysis
Assessed compatibility status of both QMS under ISO 13485:2016 or EU GMP, with a defined leading target system.
Integration strategy
QMS integration plan with milestones, responsibilities and the sequence of authorization transfers.
Authorization & certificate transfer
Submitted variation and ownership transfer applications, updated EUDAMED entries under EU 2017/745 and EU 2017/746, notified body informed.
Post-merger integration
Merged QMS under change control, closed legacy CAPA, aligned authority communication.
Quality culture alignment
Harmonized quality policies and training levels, documented and resolved friction points.
Common pitfalls
Where projects commonly fail
Regulatory due diligence only reviews the formal authorizations, not their transferability.
A valid certificate is of little use if the underlying technical documentation is incomplete or the notified body will not approve the transfer to the new owner without a renewed assessment.
QMS integration starts without a defined leading system.
If two systems operated under ISO 13485:2016 are continued in parallel, this creates conflicting processes and duplicate document control, which surface as a nonconformity in the next surveillance audit.
Authorization transfers are only begun after closing.
Variation procedures and ownership transfer have lead times; without parallel preparation, a phase arises in which regulatory responsibility for a product formally rests clearly with neither the seller nor the buyer.
EUDAMED updates under EU 2017/745 and EU 2017/746 are overlooked.
When the owner changes, actor and product registrations must be updated. Without this step, the database remains inconsistent with the actual owner.
The target's legacy CAPA is not adopted.
Open CAPA cases pass to the buyer with the business; if they are not transferred into the acquiring QMS during integration, evidence of their processing is missing in the next inspection.
FAQ
Frequently asked questions
Sources
- ISO 13485:2016 - Quality management systems for medical devices (primary standard)
- Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR) - EUDAMED registration and change of owner
- EudraLex Volume 4 (EU GMP guide) and 21 CFR Part 211 (FDA cGMP) - inspection findings and CAPA
- Writer source material M&A & PMI Support Life Sciences (Entourage, 2026-03-29)
- https://theentourage.de/expertise/ma-pmi-support-life-science/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- ISO 13485:2016 (QM system for medical devices)
- ISO 9001:2015 (QM system)
- EU 2017/745 (MDR)
- EU 2017/746 (IVDR)
- GDP guidelines 2013/C 343/01 (Good Distribution Practice for medicinal products for human use)
- EudraLex Volume 4 (EU GMP guide)
- 21 CFR Part 211 (FDA cGMP for medicinal products)
Related topics
Regulatory Affairs →
Authorization transfers and variation procedures on a change of owner
Quality Management →
QMS integration under ISO 13485:2016 and EU GMP after closing
CAPA Management →
Transferring the target's legacy CAPA into the acquiring QMS
EUDAMED →
Updating actor and product registration on a change of owner
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences